

Supplemental Disclosure for Change of Control Events

PEAK PHARMACEUTICALS, INC.
14201 N. Hayden Road, Suite A-1
Scottsdale, AZ 85260

The goal of this disclosure is to provide information with respect to a company's Change of Control event. Please address each of the below items to the best of the company's ability and to the extent they are applicable to the company's Change of Control event.

Disclosure of Change in Control and Other Material Events:

1. A description of event(s) and relevant date(s) resulting in the Change in Control.¹

On March 27, 2023, Peak Pharmaceuticals, Inc., a Nevada corporation (the "Company"), Retrieve Medical Acquisition Corp., a Delaware corporation (the "Acquisition Subsidiary") and Retrieve Medical, Inc., a Delaware corporation ("Retrieve"), entered into an Agreement and Plan of Merger and Reorganization (the "Agreement") pursuant to which the Acquisition Subsidiary was merged with and into Retrieve, with Retrieve surviving as a wholly-owned subsidiary of the Company (the "Merger"). The transaction (the "Closing") took place on March 27, 2023 (the "Closing Date"). The Company acquired, through a reverse triangular merger, all of the outstanding capital stock of Retrieve in exchange for issuing Retrieve's shareholders (the "Retrieve Shareholders"), pro-rata, an aggregate of 16,338,951 shares of the Company's common stock, par value \$0.001 per share (the "Common Stock"). As a result of the Merger, the Retrieve Shareholders became the majority shareholders of the Company.

Neil Reithinger, the sole director of the Company, approved the Agreement and the transactions contemplated under the Agreement, and on the Closing Date, resigned from his positions of Chief Executive Officer, Chief Financial Officer and sole director of the Company. The directors and shareholders of Retrieve have approved the Agreement and the transactions contemplated thereunder and as of the Closing Date own 16,338,951 shares of Common Stock in the aggregate.

Immediately following the Closing of the Merger, the Company changed its business plan to that of Retrieve. As a result of the Merger, the Company no longer meets the definition of a shell company as defined in Rule 12b-2 and thus ceased being a shell company.

Effective as of the Closing Date, Mr. Jerry Swon, was appointed as the Chief Executive Officer of the Company.

As a result of the Merger, the Company plans to take the steps to immediately change its name to "Retrieve Medical Holdings, Inc." as well as its trading symbol to better reflect its current business to its shareholders. The Company also plans on changing its fiscal year end from September 30 to December 31.

About Retrieve Medical

Retrieve's software uses data mining, clinical decision support, natural language processing, and algorithmic testing to analyze a patient's accumulated medical records and lab results in real-time generating diagnostic support guidance. By analyzing all the available data about a patient, the software is expected to produce superior diagnoses with supporting comorbidities, leading to a reduction of malpractice claims and readmission rates and increased quality of patient care. Furthermore, the product will simplify the documentation process for physicians, and reduce medical records coding overhead.

The software in its current form is designed to operate in the "Oracle/Cerner" EHR system environment. Cerner is one of the three major integrated medical database systems in the United States. The product is also an Approved Application on EPIC. Retrieve has expanded the software to work in a cloud environment, to provide improved stability, security, and version control. Further, Retrieve uses SMART on FHIR, a workflow process that an application can use to securely request access to data, and then receive and use that data, to integrate with vendor platforms that increase efficacy, reduces overhead and saves valuable time and resources in the integration and connectivity efforts. The target market for Retrieve's software is medical center emergency departments.

2. The name(s) of person(s) who acquired control and person(s) from whom control was assumed. For corporations or other business entities, please provide the name(s) of person(s) beneficially owning or controlling such corporations or entities.²

In connection with the Merger, on the Closing Date, Mr. Neil Reithinger resigned from his positions as Chief Executive Officer, Chief Financial Officer and sole director of the Company, and (i) Mr. Jerry Swon was appointed as the Chief Executive Officer of the company, (ii) Mr. Joerg Klaube was appointed as the Chief Financial Officer of the Company, and Messrs. Mark Rosenberg, Jerry Swon, Jason Pottinger, Todd Griffith and Louis C. Rose were elected to serve on the Company's Board of Directors.

3. A description of assets acquired or disposed of in connection with the Change in Control and the names of the purchaser and seller of such assets (if applicable).

As a result of the Merger, the Company acquired 100% of the issued and outstanding capital stock of Retrieve from the Retrieve Shareholders.

4. Amount and form (e.g., cash, equity securities, promissory note) of consideration paid in connection with the Change in Control.

In connection with the Merger, the Company acquired, through a reverse triangular merger, all of the outstanding capital stock of Retrieve in exchange for issuing the Retrieve Shareholders, pro-rata, an aggregate of 16,338,951 shares of the Company's Common Stock, the equivalent of 86% of the capital stock of the Company on a post-Merger basis.

5. A description of any material agreements or other events related to the Change in Control.

As disclosed above, On March 27, 2023, the Company, the Acquisition Subsidiary and Retrieve entered into an Agreement and Plan of Merger and Reorganization, pursuant to which the Acquisition Subsidiary was merged with and into Retrieve, with Retrieve surviving as a wholly-owned subsidiary of the Company. The transaction took place on March 27, 2023.

Certification:

PEAK PHARMACEUTICALS, INC.

Dated: March 27, 2023

By: /s/ Jerry E. Swon

Jerry E. Swon
Chief Executive Officer

¹ A "Change in Control" shall mean any events resulting in:

- i. Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- ii. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- iii. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- iv. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

² See, Securities Exchange Act Rule 13d-3 for determination of "beneficial owner."